Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Arrowhead Reports Third Quarter Fiscal 2009 Financial Results

Abstract:
Arrowhead Research Corporation (NASDAQ: ARWR) today announced financial results for its third fiscal quarter ended June 30 2009

Arrowhead Reports Third Quarter Fiscal 2009 Financial Results

Pasadena, CA | Posted on August 11th, 2009

THIRD QUARTER FISCAL 2009 AND RECENT COMPANY HIGHLIGHTS:

Business highlights:

o Increased ownership in carbon nanotube-based electronics films subsidiary Unidym Inc. to 67% and executed agreements to increase ownership to 70%.

o Executed license agreements for majority-owned subsidiary Calando Pharmaceuticals' Cyclosert™ drug delivery platform and associated clinical stage anti-cancer drug, IT-101, with upfront payments of $2.4 million, with potential future milestone and royalty payments.

o Restructured Unidym and Calando liabilities such that $3.6 million in liabilities was converted to $3.6 million in stockholders' equity, with an additional $500,000 converting subsequent to quarter end.

o Majority-owned Unidym, Inc. agreed to partner its bulk materials business with Continental Carbon Company, a global leader in carbon blacks, conductive blacks and carbon nanotubes, includes potential earnout of $26.5 million based on sales.

o Unidym entered into a joint development agreement with a leading global electronics manufacturer. With this partnership, Unidym is now working with two of the leading global manufacturers of LCDs to incorporate its CNT films into their display devices.

o Continued consolidation activities to further streamline Unidym and Calando operations and maximize potential for near-term opportunities while conserving cash.

Financial highlights:

o Decreased quarterly operating expenses by 51% year-over-year to $4.9 million.

o Decreased cash burn by 89% in the third quarter of fiscal 2009 compared to the same quarter in the prior year and by 35% compared to the second quarter of fiscal 2009.

o On August 6, 2009, completed an oversubscribed financing transaction that raised gross proceeds of $2.76 million.

"Our company has undergone significant transformation over the last quarter to tightly focus our business on the highest return opportunities and reduce our cost structure," stated Dr. Christopher Anzalone, Arrowhead's President and CEO. "We have made tremendous progress and are now poised to dedicate our resources to the nearest-term revenue drivers and work more actively with key partners while continuing to improve our balance sheet.

"Our resources are primarily focused on our lead subsidiary Unidym, where we see the nearest-term value creation for our shareholders. By restructuring Unidym's business model from a vertically-integrated company to one that focuses on its core competencies and on establishing partnerships with well-positioned and well-capitalized companies, we have effectively scaled back Unidym's cost structure and aggressively reduced its monthly cash burn by 50% from January to June of this year.

"As Unidym built key partnerships and made progress toward product commercialization, we strategically increased our ownership position in Unidym to 67%, and have executed agreements to reach 70%, to further maximize our stake in potential revenues, which we expect to begin seeing in modest amounts in late calendar 2009," Dr. Anzalone continued. "Funds from our recently completed private placement will assist Unidym in commercializing its carbon nanotubes for the touch panel market. As a result of established partnerships with industry leading OEMs such as Samsung Electronics, we are confident that Unidym will emerge as a dominant player in the CNT-production and application market.

"In addition to Unidym, we believe our holdings in Calando Pharmaceuticals and Nanotope, Inc. could also drive near-term value without requiring significant additional capital from Arrowhead. As we work with our subsidiaries to bring innovative new products to market, we will continue to implement prudent cost controls while maximizing partnering opportunities," Dr. Anzalone concluded.

SELECTED THIRD QUARTER FISCAL 2009 AND YEAR-TO-DATE FINANCIAL RESULTS

For third quarter ended June 30, 2009, Arrowhead reported revenues of $2.6 million, compared with $0.2 million in the same period in 2008. The increase in revenues resulted from an upfront cash payment of $2.4 million from Cerulean Pharma Inc. for a licensing agreement with Calando for further development of Calando's IT-101 drug candidate and its associated delivery platform.

Total operating expenses for the third quarter of fiscal 2009 decreased by 51% to $4.9 million, compared with total operating expenses of $10.1 million for the third quarter of fiscal 2008. Operating expenses for the third quarter of fiscal 2009 included non-cash charges of $1.7 million for in-process research and development related to the transactions to increase Arrowhead's ownership in Unidym.

Net loss for the third quarter of fiscal 2009 was ($2.5) million, or ($0.06) per diluted share based on 43.3 million weighted average shares outstanding. This compares with a net loss of ($7.5) million, or ($0.19) per diluted share on 38.9 million weighted average shares outstanding, for the third quarter of fiscal 2008.

For the nine months ended June 30, 2009, Arrowhead reported revenues of $3.6 million, compared with $1.4 million for the nine months ended June 30, 2008. Net loss for the nine months ended June 30, 2009 was ($15.8) million, or ($0.37) per share on 43.1 million weighted average shares outstanding, compared with a net loss of $18.4 million, or ($0.48) per share on 38.8 million weighted average shares outstanding, in the same period in the prior year.

The Company's net cash used in operations for the nine months ended June 30, 2009 was $12.9 million, compared with $19.2 million in the comparable fiscal 2008 period. Arrowhead's consolidated cash flows included approximately $2.5 million raised from outside investors through a note offering by Calando and the sale of $2 million of newly issued Unidym C-1 shares to TEL Ventures in the first quarter of fiscal 2009. Additionally, Unidym realized a $0.7 million gain through the sale of its equity interest in Ensysce BioSciences, Inc.

As of June 30, 2009, Arrowhead had cash and cash equivalents of $1.9 million and stockholders' equity of $3.7 million. Subsequent to the end of the third fiscal quarter, Arrowhead sold an aggregate of 9.2 million units comprised of common stock and warrants in a private placement transaction with accredited investors for gross proceeds of $2.76 million.

Conference Call

The Company will conduct a financial announcement conference call today, Monday, August 10, 2009, at 4:30 p.m. Eastern time/1:30 p.m. Pacific time to discuss the Company's results. To participate in the conference call, please dial 888-846-5003 or 480-629-9856. Investors may also access a live audio web cast of this conference call on the Company's website at www.arrowheadresearch.com.

A replay of the webcast will be available approximately two hours after the conclusion of the call. The webcast replay will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be made available until Monday, August 17, 2009. The audio replay can be accessed by dialing 800-406-7325 or 303-590-3030 and entering access ID number 4134570#.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. For example, there can be no assurance that Arrowhead or its subsidiaries will be able to sustain operations for expected periods, that we will be able to achieve or sustain targeted levels of expense reductions or that any of these entities will be successful in obtaining additional funding needed to sustain operations. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation (NASDAQ: ARWR) is a nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is seeking to build value for shareholders through the progress of majority owned subsidiaries. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications and minority investments in two privately held nanobiotech companies.

For more information, please click here

Contacts:
Arrowhead Research Corporation
201 South Lake Avenue, Suite 703
Pasadena, CA 91101

Telephone: (626) 304-3400
Fax: (626) 304-3401

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014

Research yields material made of single-atom layers that snap together like Legos November 25th, 2014

Blu-ray disc can be used to improve solar cell performance: Data storage pattern transferred to solar cell increases light absorption November 25th, 2014

A*STAR SIMTech wins international award for breaking new ground in actuators: SIMTech invention can be used in an array of industries, and is critical for next generation ultra-precision systems November 24th, 2014

Display technology/LEDs/SS Lighting/OLEDs

Spiraling light, nanoparticles and insights into life’s structure November 19th, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

QD Vision Wins Prestigious Presidential Green Chemistry Challenge Award from the U.S. Environmental Protection Agency October 16th, 2014

Beyond LEDs: Brighter, new energy-saving flat panel lights based on carbon nanotubes - Planar light source using a phosphor screen with highly crystalline single-walled carbon nanotubes (SWCNTs) as field emitters demonstrates its potential for energy-efficient lighting device October 14th, 2014

Investments/IPO's/Splits

Nanometrics Announces Upcoming Investor Events November 19th, 2014

Eight19 secures £1m funding: Investment to develop production technology, and expand commercial activities for organic photovoltaics November 19th, 2014

Arrowhead to Present at Upcoming Conferences November 15th, 2014

Harris & Harris Group Reports Financial Statements as of September 30, 2014 November 11th, 2014

Nanotubes/Buckyballs

Tesla NanoCoatings Increasing Use of SouthWest NanoTechnologies Carbon Nanotubes (CNTs) for its Infrastructure Coatings and Paints: High Quality SMW™ Specialty Multi-wall Carbon Nanotubes Incorporated into Teslan®-brand coatings used by Transportation, Oil and Gas Companies November 19th, 2014

Graphene/nanotube hybrid benefits flexible solar cells: Rice University labs create novel electrode for dye-sensitized cells November 17th, 2014

SouthWest NanoTechnologies to Demonstrate 3D Capacitive Touch Sensor Featuring Transparent, Thermoformed Carbon Nanotube Ink at Printed Electronics USA 2014 (Booth J25) -- “Conductive and Semiconducting Single-Wall Carbon Nanotube Inks” will be Topic of Company Presentation November 10th, 2014

Neural Canals Produced in Iran for Recovery of Sciatica Nerve November 8th, 2014

Nanoelectronics

Leti Will Present 17 Papers at 2014 IEDM; the Highest-ever Total Includes Four Invited Papers: Institute also Will Present its Latest Results in Key Technologies and Its Roadmap for Silicon Nano-technologies at Workshop November 13th, 2014

Breakthrough in molecular electronics paves the way for DNA-based computer circuits in the future: DNA-based programmable circuits could be more sophisticated, cheaper and simpler to make October 27th, 2014

NIST offers electronics industry 2 ways to snoop on self-organizing molecules October 22nd, 2014

Materials for the next generation of electronics and photovoltaics: MacArthur Fellow develops new uses for carbon nanotubes October 21st, 2014

Announcements

Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014

Research yields material made of single-atom layers that snap together like Legos November 25th, 2014

Blu-ray disc can be used to improve solar cell performance: Data storage pattern transferred to solar cell increases light absorption November 25th, 2014

Cooling with the coldest matter in the world November 24th, 2014

Patents/IP/Tech Transfer/Licensing

Dicerna Announces License Agreement with Tekmira to Advance Dicerna’s PH1 Development Program November 17th, 2014

First genetic-based tool to detect circulating cancer cells in blood: NanoFlares light up individual cells if breast cancer biomarker is present November 17th, 2014

Ki-Bum Lee Patents Technology To Advance Stem Cell Therapeutics November 13th, 2014

'Direct writing' of diamond patterns from graphite a potential technological leap November 5th, 2014

Financial Reports

Harris & Harris Group Reports Financial Statements as of September 30, 2014 November 11th, 2014

Harris & Harris Group to Host Conference Call on Third Quarter 2014 Financial Results on November 12, 2014 November 3rd, 2014

Aspen Aerogels, Inc. Schedules Third Quarter 2014 Earnings Release and Conference Call for November 6, 2014 October 17th, 2014

Nanometrics to Announce Third Quarter Financial Results on October 28, 2014 October 8th, 2014

Alliances/Partnerships/Distributorships

New research project supports internationalisation in nano-research: Launch of new “Baltic Sea Network” November 22nd, 2014

UO-industry collaboration points to improved nanomaterials: University of Oregon microscope puts spotlight on the surface structure of quantum dots for designing new solar devices November 20th, 2014

A novel method for identifying the body’s ‘noisiest’ networks November 19th, 2014

Field-emission plug-and-play solution for microwave electron guns: To simplify the electron emission mechanism involved in microwave electron guns, a team of researchers has created and demonstrated a field-emission plug-and-play solution based on ultrananocrystalline diamond November 18th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More












ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE